A0350000
Allopurinol
European Pharmacopoeia (EP) Reference Standard
동의어(들):
1H-Pyrazolo(3,4-d)pyrimidin-4-ol, 4-Hydroxypyrazolo(3,4-d)pyrimidine, 4-Hydroxypyrazolo[3,4-d]pyrimidine, HPP
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C5H4N4O
CAS Number:
Molecular Weight:
136.11
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
allopurinol
제조업체/상표
EDQM
mp
>300 °C (lit.)
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
O=C1NC=Nc2[nH]ncc12
InChI
1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
InChI key
OFCNXPDARWKPPY-UHFFFAOYSA-N
유전자 정보
human ... XDH(7498)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. For further information and support, including product information leaflets, please go to the website of the issuing Pharmacopoeia.
애플리케이션
Allopurinol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
생화학적/생리학적 작용
Inhibitor of xanthine oxidase and de novo pyrimidine biosynthesis. A classical agent in treatment of hyperuricemia and gout.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Oral - Skin Sens. 1
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
Sarah Leighton et al.
Experimental dermatology, 22(3), 189-194 (2013-02-08)
Exposure to solar ultraviolet (UV) radiation suppresses adaptive immune responses. This contributes to skin carcinogenesis but may protect from some autoimmune diseases. However, the molecular changes occurring within UV-exposed skin that precipitate the downstream events leading to immune suppression are
Gisele Zandman-Goddard et al.
Rheumatology (Oxford, England), 52(6), 1126-1131 (2013-02-09)
To assess the adherence and persistence with allopurinol therapy among gout patients and to identify risk factors for therapy discontinuation. The study population included adults in Maccabi Healthcare Services, a 2-million member health maintenance organization in Israel, who were diagnosed
Essack Mitha et al.
Rheumatology (Oxford, England), 52(7), 1285-1292 (2013-03-15)
To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial. Hyperuricaemic adults (n = 248) from South
Tsen-Fang Tsai et al.
American journal of clinical dermatology, 11(4), 225-232 (2010-06-01)
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has
Sheena N Ramasamy et al.
Drug safety, 36(10), 953-980 (2013-07-23)
Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in tandem with the growing prevalence of gout globally. This exposes more patients to the risk of allopurinol hypersensitivity (AH), a rare adverse reaction
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.